

## Patent Claims

1. A T-cell immune response inhibitor that comprises a targeted pathogen nucleic acid vaccine and said nucleic acid vaccine's expression protein antigen; or a targeted pathogen nucleic acid vaccine and said nucleic acid vaccine's expression protein antigen's active polypeptide; or an inactivated pathogen and said targeted pathogen's nucleic acid vaccine.
2. A T-cell immune response inhibitor according to Patent Claim 1, wherein said T-cell immune response inhibitor comprises a single package or a mixture of the targeted pathogen nucleic acid vaccine and said nucleic acid vaccine's expression protein antigen.
3. A T-cell immune response inhibitor according to Patent Claim 2, wherein the physical proportion of said T-cell immune response inhibitor's targeted pathogen nucleic acid vaccine and said nucleic acid vaccine's expression protein antigen is 2:1 to 10:1.
4. A T-cell immune response inhibitor according to Patent Claim 3, wherein the physical proportion of said T-cell immune response inhibitor's targeted pathogen nucleic acid vaccine and said nucleic acid vaccine's expression protein antigen is 5:1.
5. A T-cell immune response inhibitor according to Patent Claim 1, wherein said T-cell immune response inhibitor comprises a single package or a mixture of the targeted pathogen nucleic acid vaccine and said nucleic acid vaccine's expression protein antigen's active polypeptide.
6. A T-cell immune response inhibitor according to Patent Claim 5, wherein the physical proportion of said T-cell immune response inhibitor's targeted pathogen nucleic acid vaccine and said nucleic acid vaccine's expression protein antigen's active peptide is 1:5 to 5:1.
7. A T-cell immune response inhibitor according to Patent Claim 1, wherein said T-cell immune response inhibitor comprises a single package or a mixture of the inactivated pathogen and the targeted pathogen nucleic acid vaccine.
8. A T-cell immune response inhibitor according to Patent Claim 7, wherein the physical proportion of the inactivated pathogen and the targeted pathogen nucleic acid vaccine in said T-cell immune response inhibitor is 1:2 to 1:10.
9. Any one of the T-cell immune response inhibitors according to Patent Claims 1 to 8, wherein said T-cell immune response inhibitor also comprises an immunological adjuvant.
10. Any one of the T-cell immune response inhibitors according to Patent Claims 1 to 8, wherein said nucleic acid vaccine is a eukaryote cell expression carrier containing a protein antigen encoded gene.

11. A T-cell immune response inhibitor according to Patent Claim 10, wherein the regulatory protein antigen encoded gene expression promoter in said eukaryote cell expression carrier is RSV, CMV and SV40 viral promoters.

12. A T-cell immune response inhibitor according to Patent Claim 10, wherein said eukaryote cell expression carrier is a plasmid expression carrier, virus or bacteriophage expression carrier, and the expression carrier is formed of plasmid DNA and viral or bacteriophage DNA or the expression carrier is formed of plasmid DNA and a chromosomal DNA fragment.

13. A T-cell immune response inhibitor according to Patent Claim 10, wherein said protein antigen encoded gene's DNA may be artificially synthesized or derived from double-stranded DNA obtained from microbes, eukaryote and plant cells or tissues.

14. A T-cell immune response inhibitor according to Patent Claims 2, 3 or 4, wherein said protein antigen is protein obtained through artificial synthesis or through biological production.

15. A T-cell immune response inhibitor according to Patent Claims 5 or 6, wherein said protein antigen's active polypeptides is obtained through artificial synthesis or biological production.

16. A T-cell immune response inhibitor according to Patent Claim 14, wherein the production of said biological organism may utilize enhanced production of Escherichia coli or bacillocin or saccharomycete or other eukaryote cellular organisms under artificial culture conditions.

17. A T-cell immune response inhibitor according to Patent Claim 15, wherein the production of said biological organism may utilize enhanced production of Escherichia coli or bacillocin or saccharomycete or other eukaryote cellular organisms under artificial culture conditions.

18. A T-cell immune response inhibitor according to Patent Claims 7 or 8, wherein said inactivated pathogen may use commonly known methods to separate and produce the virus, pathogenic bacteria, parasite and allergenic substance to obtain the noninfectious pathogen.

19. A T-cell immune response inhibitor according to Patent Claim 18, wherein said inactivated pathogen may be mixed directly with the nucleic acid vaccine or after emulsifying with mineral oil the inactivated pathogen may be mixed with the nucleic acid vaccine.